IPO - Phio Pharmaceuticals Corp.

Form Type: S-1

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000168316825000460

Filing Summary: Phio Pharmaceuticals Corp. is filing a Registration Statement on Form S-1 to register up to 5,930,016 shares of its common stock for resale by selling stockholders. The shares include those issuable upon exercise of various warrants with terms ranging from 24 months to 5 years, with a potential gross proceeds estimate of $17.5 million if all warrants are exercised in cash. The company emphasizes the unpredictability of warrant exercises and acknowledges it will not receive proceeds from the sale of shares being resold but may receive funds from warrant exercises. The common stock is listed on The Nasdaq Capital Market under the ticker symbol 'PHIO'. The last reported sale price prior to the filing was $2.77 per share. The company is identified as a clinical stage biotechnology firm focusing on cancer treatments utilizing its proprietary INTASYL technology, which aims to enhance immune cell effectiveness against tumor cells. Their lead product, PH-762, is in a Phase 1b clinical trial for treating cutaneous squamous cell carcinoma and other cancers, showing promising anti-tumoral effects in preclinical studies. The prospectus carries cautionary notes on the risks associated with investing, including those linked to their unproven technology and market uncertainties.

Document Link: View Document